KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Receivables (2016 - 2025)

Historic Receivables for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $346.0 million.

  • Halozyme Therapeutics' Receivables rose 2110.01% to $346.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $346.0 million, marking a year-over-year increase of 2110.01%. This contributed to the annual value of $328.8 million for FY2024, which is 3977.08% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Receivables stood at $346.0 million for Q3 2025, which was up 2110.01% from $316.3 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Receivables registered a high of $346.0 million during Q3 2025, and its lowest value of $92.1 million during Q4 2021.
  • For the 5-year period, Halozyme Therapeutics' Receivables averaged around $224.7 million, with its median value being $231.1 million (2022).
  • Its Receivables has fluctuated over the past 5 years, first skyrocketed by 30401.87% in 2021, then tumbled by 2749.11% in 2023.
  • Halozyme Therapeutics' Receivables (Quarter) stood at $92.1 million in 2021, then soared by 150.85% to $231.1 million in 2022, then increased by 1.79% to $235.2 million in 2023, then soared by 39.77% to $328.8 million in 2024, then grew by 5.26% to $346.0 million in 2025.
  • Its last three reported values are $346.0 million in Q3 2025, $316.3 million for Q2 2025, and $304.6 million during Q1 2025.